Integrated radiosurgical treatment of resectable pancreatic head carcinoma

被引:5
|
作者
Crucitti, F
Doglietto, GB
Frontera, D
Viola, G
Morganti, AG
Valentini, V
Alfonsi, G
Trodella, L
Cellini, N
机构
[1] Catholic Univ, Sch Med, Dept Surg, I-00168 Rome, Italy
[2] Catholic Univ, Sch Med, Dept Radiotherapy, I-00168 Rome, Italy
关键词
pancreatic carcinoma; surgical resection; intraoperative radiotherapy;
D O I
10.1097/00006676-199801000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Thirty-six patients with pancreatic head carcinoma entered a protocol, but only 20 were suitable for resection and evaluation of long-term survival. They were nine males and 11 females, with a mean age of 64.3 years. Following surgical resection, 10 Gy was delivered to the tumor bed intraoperatively. Postoperative radiotherapy was performed 4-6 weeks after surgery: patients were treated with 50.4 Gy (1.8 Gy/day, 5 days/week) to the tumor and nodal bed. Since 1991, 10 patients have also received preoperative short-course radiotherapy (5 Gy) of the liver and pancreas. Postoperative morbidity was 25%; two postoperative deaths were observed in patients with locally advanced neoplasms, in whom a vascular resection was also performed. Only 14 patients started postoperative radiotherapy, which was interrupted in two cases. At present, 14 patients are dead and four are alive and disease free. The local recurrence rate was 11.1% and distant metastases were observed in 66.7% of cases. The median actuarial survival was 11.9 months, but it was 18.5 months in patients with disease-free resection margins. A significantly better survival was also observed in patients submitted to short-course preoperative radiotherapy. These preliminary results show that intraoperative and perioperative radiotherapy is feasible and may improve local control of disease. Unfortunately, these results are not matched by a significant improvement in survival due to the high incidence of intraabdominal metastases. Thus, new therapeutic modalities, including preoperative radiotherapy (with or without chemotherapy), should be tested.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 50 条
  • [21] Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma
    Moulla, Yusef
    Petersen, Tim-Ole
    Maiwald, Bettina
    Bailis, Nikolaos
    Kreuser, Nicole
    Lordick, Florian
    Seehofer, Daniel
    Sucher, Robert
    Hecker, Martin
    Hoffmeister, Albrecht
    Jansen-Winkeln, Boris
    Gockel, Ines
    CHIRURG, 2020, 91 (04): : 319 - 328
  • [22] CARCINOMA OF THE PANCREATIC HEAD
    不详
    LANCET, 1948, 252 (JUL17): : 105 - 106
  • [23] PANCREATIC HEAD CARCINOMA
    LYGIDAKIS, NJ
    TYTGAT, KMAJ
    HEPATO-GASTROENTEROLOGY, 1989, 36 (06) : 409 - 411
  • [24] OPERATION OF CHOICE FOR RESECTABLE CARCINOMA OF THE HEAD OF THE PANCREAS
    TSUCHIYA, R
    TSUNODA, T
    YAMAGUCHI, T
    INTERNATIONAL JOURNAL OF PANCREATOLOGY, 1990, 6 (04) : 295 - 306
  • [25] CT FINDINGS OF RESECTABLE PANCREATIC-CARCINOMA
    MARUYAMA, M
    OHASHI, K
    ITAI, Y
    GASTROINTESTINAL RADIOLOGY, 1980, 5 (04): : 387 - 388
  • [26] Muscle Index as an Indicator for resectable Pancreatic Carcinoma
    Manekeller, Steffen
    ZENTRALBLATT FUR CHIRURGIE, 2017, 142 (02): : 150 - 151
  • [27] Trends in the Treatment of Resectable Pancreatic Adenocarcinoma
    Raigani, Siavash
    Ammori, John
    Kim, Julian
    Hardacre, Jeffrey M.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 18 (01) : 113 - 123
  • [28] Treatment of Borderline Resectable Pancreatic Cancer
    Amanda B. Cooper
    Ching-Wei D. Tzeng
    Matthew H. G. Katz
    Current Treatment Options in Oncology, 2013, 14 : 293 - 310
  • [29] Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
    Massani, Marco
    Stecca, Tommaso
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Janssen, Quisette P.
    O'Reilly, Eileen M.
    Van Eijck, Casper H. J.
    Groot Koerkamp, Bas
    FRONTIERS IN ONCOLOGY, 2020, 10